Skip to main
LXEO

LXEO Stock Forecast & Price Target

LXEO Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lexeo Therapeutics Inc. is positioned favorably in the gene therapy sector for cardiovascular diseases, particularly with promising advances in its lead candidates, LX2006 and LX2020. The company projects a significant market penetration for LX2006, anticipating a cumulative reach of 25% of US cardiac Friedreich's ataxia patients by 2035, potentially increasing to a 60% market share as pivotal timelines accelerate. Additionally, recent data demonstrate notable improvements in patient outcomes, with high-dose cohorts achieving mean reductions of approximately 14% in premature ventricular contractions (PVCs) and 22% in non-sustained ventricular tachycardia (NSVT), indicating the potential effectiveness of Lexeo's therapies in addressing high unmet medical needs.

Bears say

The outlook on Lexeo Therapeutics's stock appears negative due to the reliance on replicating early positive activity data in subsequent trials, as any failure to reproduce these results or the emergence of safety signals could severely impact the company's valuation. Furthermore, uncertainties regarding the evolving regulatory landscape concerning trial designs—such as size, endpoints, and follow-up—may introduce delays that could hinder progress and result in further price target reductions. Overall, these factors contribute to a precarious financial situation for the company, potentially undermining investor confidence in its clinical programs.

LXEO has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lexeo Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lexeo Therapeutics Inc (LXEO) Forecast

Analysts have given LXEO a Buy based on their latest research and market trends.

According to 8 analysts, LXEO has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lexeo Therapeutics Inc (LXEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.